The application of SGLT-2 can bring clinical benefits to early CKD patients (The et al., 2023), and even CKD patients who have severely damaged renal function may also have certain potential benefits (Heerspink et al., 2023a). The gene discussed is SLC5A2; the disease is chronic kidney disease.